Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Praxis Precision Medicines ( (PRAX) ) has shared an announcement.
Praxis Precision Medicines is advancing its CNS disorder therapies, with promising developments in its late-stage drugs: relutrigine for developmental and epileptic encephalopathies, ulixacaltamide for essential tremor, and vormatrigine for epilepsy. The company is expanding its EMBOLD study and planning new trials, supported by strong financials and a focus on precision medicine. These efforts highlight significant progress towards potentially transformative treatments in the neurological space.
See more insights into PRAX stock on TipRanks’ Stock Analysis page.
